Literature DB >> 21545558

Benzodiazepines, opioids and driving: an overview of the experimental research.

Stefanie Y Leung1.   

Abstract

ISSUES: Road crashes contribute significantly to the total burden of injury in Australia, with the risk of injury being associated with the presence of drugs and/or alcohol in the driver's blood. Increasingly, some of the most commonly detected drugs include prescription medicines, the most notable of these being benzodiazepines and opioids. However, there is a paucity of experimental research into the effects of prescribed psychoactive drugs on driving behaviours. APPROACH: This paper provides an overview of experimental studies investigating the effects of prescribed doses of benzodiazepines and opioids on driving ability, and points to future directions for research. KEY
FINDINGS: There is growing epidemiological evidence linking the therapeutic use of benzodiazepines and opioids to an increased crash risk. However, the current experimental literature remains unclear. Limitations to study methodologies have resulted in inconsistent findings. IMPLICATIONS: Limited experimental evidence exists to inform policy and guidelines regarding fitness-to-drive for patients taking prescribed benzodiazepines and opioids.
CONCLUSION: Further experimental research is required to elucidate the effects of these medications on driving, under varying conditions and in different medical contexts. This will ensure that doctors prescribing benzodiazepines and opioids are well informed, and can appropriately advise patients of the risks associated with driving whilst taking these medications.
© 2011 Australasian Professional Society on Alcohol and other Drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21545558     DOI: 10.1111/j.1465-3362.2011.00311.x

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  16 in total

1.  Prevalence of alcohol and other drugs in fatally injured drivers.

Authors:  Joanne E Brady; Guohua Li
Journal:  Addiction       Date:  2012-08-20       Impact factor: 6.526

2.  Latent Classes of Polydrug Users as a Predictor of Crash Involvement and Alcohol Consumption.

Authors:  Michael Scherer; Eduardo Romano; Robert Voas; Eileen Taylor
Journal:  J Stud Alcohol Drugs       Date:  2018-05       Impact factor: 2.582

3.  Marijuana as a predictor of concurrent substance use among motor vehicle operators.

Authors:  Michael Scherer; Robert B Voas; Debra Furr-Holden
Journal:  J Psychoactive Drugs       Date:  2013 Jul-Aug

4.  Prevalence of Self-Reported Prescription Drug Use in a National Sample of U.S. Drivers.

Authors:  Tara Kelley-Baker; Geetha Waehrer; Robin A Pollini
Journal:  J Stud Alcohol Drugs       Date:  2017-01       Impact factor: 2.582

5.  Correlates of opioid and benzodiazepine co-prescription among people living with HIV in British Columbia, Canada: A population-level cohort study.

Authors:  Stephanie Parent; Seonaid Nolan; Nadia Fairbairn; Monica Ye; Anthony Wu; Julio Montaner; Rolando Barrios; Lianping Ti
Journal:  Int J Drug Policy       Date:  2019-03-18

6.  Intercorrelation of Alcohol and Other Drug Use Disorders among a National Sample of Drivers.

Authors:  Michael Scherer; Sarah Canham; Robert B Voas; C Debra Furr-Holden
Journal:  J Psychoactive Drugs       Date:  2017-08-28

7.  Adverse Drug Events due to Central Nervous System Depressant Drugs in Pediatric Patients With or Without Surgery.

Authors:  Marumi Yamamoto; Yoshinori Ohta; Mio Sakuma; Chisa Matsumoto; Takeshi Morimoto
Journal:  J Pediatr Pharmacol Ther       Date:  2020

Review 8.  Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review.

Authors:  Toni M Rudisill; Motao Zhu; George A Kelley; Courtney Pilkerton; Brandon R Rudisill
Journal:  Accid Anal Prev       Date:  2016-08-29

Review 9.  Benzodiazepine harm: how can it be reduced?

Authors:  Malcolm Lader
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

10.  Newly initiated opioid treatment and the risk of fall-related injuries. A nationwide, register-based, case-crossover study in Sweden.

Authors:  Karin C Söderberg; Lucie Laflamme; Jette Möller
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.